Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal
capillaries in the foveolar region of unknown cause for retinal telangiectasia.
In Idiopathic Macular Telangiectasia, proliferative changes occur in the deep retinal
capillary network, leading to intraretinal neovascularization that, unlike in age-related
macular degeneration, seems to be retinal rather than choroidal in origin. Before the
hemorrhagic and fibrotic state, these vessels may lead to exudation and decrease in the
visual acuity. Long-term visual prognosis in patients with this complication may be poor and
treatment with laser photocoagulation is unproven. Although newly reported treatment, by
photodynamic therapy for neovascular membrane associated with Idiopathic Macular
Telangiectasia, may show vision and angiographic stability in a few cases, the improvement
may be transient. VEGF has been implicated as the major angiogenic stimulus responsible for
neovascularization in AMD, ensuing specific anti-VEGF treatment in these cases.
The purpose of the study is to evaluate intravitreal injection of bevacizumab (1.25mg/0.05ml)
in the treatment of Idiopathic Macular Telangiectasia.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.